Evidence map›Paper›PMID 38801502›Full record

ArticleAIDS and behavior2024

Predictors of PrEP Retention and Attrition in an Urban Publicly Funded Safety-net Specialty Clinic.

Kate Drezner, Megan Coleman, Adam Visconti, Chantil Thomas, Jason Beverley, Rachel E Harold, B W Furness

Abstract read
In one paragraph

Article in AIDS and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kate DreznerDistrict of Columbia Department of Health, Washington, DC, USA. Kate.drezner@dc.gov.ORCID http://orcid.org/0009-0000-2693-2701
Megan ColemanDistrict of Columbia Department of Health, Washington, DC, USA.
Adam ViscontiDepartment of Family Medicine, MedStar Georgetown University, Washington, DC, USA.
Chantil ThomasDistrict of Columbia Department of Health, Washington, DC, USA.
Jason BeverleyDistrict of Columbia Department of Health, Washington, DC, USA.
Rachel E HaroldDistrict of Columbia Department of Health, Washington, DC, USA.
B W FurnessCenters for Disease Control and Prevention, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3035-1461

Funding

Health Department Demonstration Projects for Comprehensive Prevention, Care, Behavioral Health, and Social Services for Men Who Have Sex with Men of Color at Risk for and Living with HIV InfectionU62PS005036 · PS · DC DEPARTMENT OF HEALTH · PI ROCHA, NESTOR · 2015 to 2015
$1.8M
CDC HHS 1U62PS005036CDC HHS NU62PS005036-04-00Intramural CDC HHS CC999999NCHHSTP CDC HHS U62 PS005036
6 · The paper itself

Abstract

Pre-exposure prophylaxis (PrEP) is an effective tool for human immunodeficiency virus (HIV) prevention. The purpose of this study is to identify correlates of PrEP retention using patient data from an urban, publicly funded safety-net clinic in Washington, DC. Cox proportional hazards regression, logistical regression, and survival curves were used to assess the association of age, gender, race/ethnicity, insurance, number of partners, and sexually transmitted infection (STI) diagnosis at PrEP initiation with time on PrEP. From August 2016-December 2020, 1,126 people were prescribed PrEP - patients were mostly Black (44.8%) or Latinx (30.4%) and identified as cisgender men (84.6%). Half had no insurance (49.1%), with the remaining patients reporting private (28.9%) or public (21.5%) insurance. Age at PrEP prescription ranged from 15 to 66 with 80% being 20 to 39 years. For the 87.7% (n = 987) of patients who discontinued PrEP, mean PrEP time was 158 days and median was 28 days. The highest rates of discontinuation were observed within the first month with 44.3% discontinuing by day 30, 52.3% by 3 months, and 73.2% by 1 year. Cisgender women, transgender persons, and those younger than 30 years were more likely to discontinue PrEP. Latinx and patients with less than 3 male partners in the last 90 days were less likely to discontinue PrEP. We demonstrated a high level of PrEP uptake among populations disproportionally affected by HIV. Future analyses are needed to examine ways of reducing barriers to PrEP initiation and improving PrEP adherence.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSafety-net ProvidersUrban PopulationAdolescentAdultAgedDistrict of ColumbiaDrug MonitoringFemaleHumansMaleMiddle AgedSexually Transmitted DiseasesSexual PartnersAnti-HIV AgentsHIV/AIDSHIV PreventionMen who have sex with men (MSM)PrEPSTI Clinic

Identifiers

PMID38801502
PMCPMC11325486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.